Compare Oklo Inc (OKLO) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oklo Inc vs Zoetis Inc — how do they compare? Oklo Inc trades at $34.7 (market cap $6.43B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 4.7× Oklo Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Oklo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oklo Inc for 32 Days and Zoetis Inc for 70 Days on average.
| OKLO | ZTS | |
|---|---|---|
Market Cap | $6.43B | $30.20B |
Volume | 16,238,368 | 6,175,327 |
Sector | Utilities | Health |
52-Week High | $174.14 | $147.53 |
52-Week Low | $34.57 | $69.09 |
Typical Hold Time | 32 Days | 70 Days |
Enterprise Value | $3.97B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKLO trades at $34.57, down 6.11% with bearish technical signals. The company shows no revenue in 2025 and negative net income of -$105.66M, though analyst consensus remains strong with 71% buy ratings and a $78.63 price target. Recent news highlights nuclear industry momentum but questions OKLO's commercialization timeline versus established peers.
Outlook hinges on project execution amid substantial cash burn. High institutional financing supports growth but dilution risks persist. The stock offers speculative upside if nuclear contracts materialize, but faces near-term execution and competitive challenges in the small modular reactor market.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
